Pan when in doubt Today’s mid-stage Neurocrine Biosciences / Takedas Luvadaxistat failure in schizophrenia-negative symptoms is disappointing, but it may not mark the end of the road for this project The Phase II Interact study failed their primary endpoint, changes in PANSS-NSFS score from baseline However, two secondary endpoints on cognitive score were nominally positive, the companies said Given this finding and the unmet need in managing negative schizophrenia symptoms, Neurocrine and Takeda are expected to continue with Luvadaxistat, which is believed to be the NMDA- Activity Increases Addressing NMDA Receptor Hypofunction Associated with Schizophrenia Symptoms Still, today’s setback is unlikely to dispel concerns about the NMDA hypothesis, which also hit a blow in February with the failure of Concert Pharmaceuticals’ CTP-692 According to Stifel analysts, the two molecules addressed different patient populations and worked differently – CTP-692 is a deuterated form of D-serine, a co-agonist of the NMDA receptor, while Luvadaxistat inhibits D-amino acid oxidase, the enzyme that D degrades -serine Neurocrine, which last June its V Earnings signed with Takeda via Luvadaxistat fell 6% this morning


World News – GB – Neurocrine searches for the silver lining in schizophrenia failure